Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide Dose-Ranging Study in Obesity
NCT00112021Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2005
- Primary completion
- Nov 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Pramlintide Acetate with Placebo (2 arms). Primary endpoints: Effect of pramlintide on body weight at 16 weeks and Safety and tolerability of pramlintide at 16 weeks. Started May 2005; status: completed.
02
Drugs
pramlintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00112021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112021.